Simian Immunodeficiency Virus Macaque Models of HIV Latency

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2011 Jan 19

PMID 21242894

Citations 17

Authors

Jesse D Deere

Raymond F Schinazi

Thomas W North

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review will focus on recent developments in several nonhuman primate models of AIDS. These models are being used to address viral latency and persistence during antiretroviral therapy in studies that are not feasible in humans.

Recent Findings: Further characterization of the various macaque models of AIDS has demonstrated that several aspects of viral persistence during antiretroviral therapy model HIV-1 infection in humans, including viral decay kinetics. Widespread distribution of viral RNA and viral DNA has been detected in many tissue organs. In addition, the brain has been identified as a site of persistent viral DNA.

Summary: The macaque models of AIDS are well suited for addressing viral persistence during antiretroviral therapy, including viral latency, residual replication, and tissue organ distribution.

Citing Articles

Microphysiological model reveals the promise of memory-like natural killer cell immunotherapy for HIV cancer.

Ayuso J, Farooqui M, Virumbrales-Munoz M, Denecke K, Rehman S, Schmitz R Nat Commun. 2023; 14(1):6681.

PMID: 37865647 PMC: 10590421. DOI: 10.1038/s41467-023-41625-8.

Opioid abuse and SIV infection in non-human primates.

Deshetty U, Ray S, Singh S, Buch S, Periyasamy P J Neurovirol. 2023; 29(4):377-388.

PMID: 37418108 PMC: 10729652. DOI: 10.1007/s13365-023-01153-z.

Psychosocial Stress Alters the Immune Response and Results in Higher Viral Load During Acute Simian Immunodeficiency Virus Infection in a Pigtailed Macaque Model of Human Immunodeficiency Virus.

Guerrero-Martin S, Rubin L, McGee K, Shirk E, Queen S, Li M J Infect Dis. 2021; 224(12):2113-2121.

PMID: 33970274 PMC: 8672752. DOI: 10.1093/infdis/jiab252.

Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.

Wang X, Xu H Viruses. 2021; 13(2).

PMID: 33670027 PMC: 7926539. DOI: 10.3390/v13020335.

HIV latency reversal research and the potential effects on the central nervous system: is concern warranted?.

Anderson A, Schinazi R, Tyor W J Int AIDS Soc. 2016; 19(1):21008.

PMID: 27166355 PMC: 4862966. DOI: 10.7448/IAS.19.1.21008.

References

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

Chun T, Stuyver L, Mizell S, Ehler L, Mican J, Baseler M . Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997; 94(24):13193-7. PMC: 24285. DOI: 10.1073/pnas.94.24.13193. View

Wong J, Strain M, Porrata R, Reay E, Sankaran-Walters S, Ignacio C . In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 2010; 6(1):e1000748. PMC: 2813272. DOI: 10.1371/journal.ppat.1000748. View

North T, Van Rompay K, Higgins J, Matthews T, Wadford D, Pedersen N . Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol. 2005; 79(12):7349-54. PMC: 1143671. DOI: 10.1128/JVI.79.12.7349-7354.2005. View

Van Rompay K . Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 2009; 85(1):159-75. DOI: 10.1016/j.antiviral.2009.07.008. View

Deere J, Higgins J, Cannavo E, Villalobos A, Adamson L, Fromentin E . Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One. 2010; 5(7):e11640. PMC: 2909142. DOI: 10.1371/journal.pone.0011640. View

Hofman M, Higgins J, Matthews T, Pedersen N, Tan C, Schinazi R . Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004; 48(9):3483-90. PMC: 514752. DOI: 10.1128/AAC.48.9.3483-3490.2004. View

Marcondes M, Flynn C, Huitron-Rezendiz S, Watry D, Zandonatti M, Fox H . Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS. 2009; 23(10):1187-95. PMC: 2698130. DOI: 10.1097/QAD.0b013e32832c4af0. View

Finzi D, Blankson J, Siliciano J, Margolick J, Chadwick K, Pierson T . Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999; 5(5):512-7. DOI: 10.1038/8394. View

10.

Hatziioannou T, Ambrose Z, Chung N, Piatak Jr M, Yuan F, Trubey C . A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A. 2009; 106(11):4425-9. PMC: 2657417. DOI: 10.1073/pnas.0812587106. View

11.

Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

12.

Lewis M, Norelli S, Collins M, Letizia Barreca M, Iraci N, Chirullo B . Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology. 2010; 7:21. PMC: 2853490. DOI: 10.1186/1742-4690-7-21. View

13.

Giuffre A, Higgins J, Buckheit Jr R, North T . Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother. 2003; 47(5):1756-9. PMC: 153320. DOI: 10.1128/AAC.47.5.1756-1759.2003. View

14.

North T, Higgins J, Deere J, Hayes T, Villalobos A, Adamson L . Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol. 2009; 84(6):2913-22. PMC: 2826073. DOI: 10.1128/JVI.02356-09. View

15.

Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373(6510):123-6. DOI: 10.1038/373123a0. View

16.

Ratai E, Bombardier J, Joo C, Annamalai L, Burdo T, Campbell J . Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One. 2010; 5(5):e10523. PMC: 2866543. DOI: 10.1371/journal.pone.0010523. View

17.

Tobin N, Learn G, Holte S, Wang Y, Melvin A, McKernan J . Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005; 79(15):9625-34. PMC: 1181593. DOI: 10.1128/JVI.79.15.9625-9634.2005. View

18.

Tsai C, Follis K, Sabo A, Beck T, Grant R, Bischofberger N . Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995; 270(5239):1197-9. DOI: 10.1126/science.270.5239.1197. View

19.

Balzarini J, Weeger M, Camarasa M, De Clercq E, Uberla K . Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun. 1995; 211(3):850-6. DOI: 10.1006/bbrc.1995.1890. View

20.

Jiang Y, Tian B, Saifuddin M, Agy M, Emau P, Cairns J . RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther. 2009; 6:23. PMC: 2780452. DOI: 10.1186/1742-6405-6-23. View